{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:06:47Z","timestamp":1789056407069,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omta.2026.201767","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T16:21:21Z","timestamp":1779985281000},"page":"201767","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical evaluation of AAV2 anti-VEGF gene therapy using scFv for choroidal neovascularization"],"prefix":"10.1016","volume":"34","author":[{"given":"Xin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8518-5766","authenticated-orcid":false,"given":"Guangzuo","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201767_bib1","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/1804038","article-title":"The Potential of Single-Chain Variable Fragment Antibody: Role in Future Therapeutic and Diagnostic Biologics","volume":"2024","author":"Gezehagn Kussia","year":"2024","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.omta.2026.201767_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nbt.1791","article-title":"Beyond natural antibodies: the power of in vitro display technologies","volume":"29","author":"Bradbury","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omta.2026.201767_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/antib8020028","article-title":"David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments","volume":"8","author":"Bates","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.omta.2026.201767_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/980250","article-title":"scFv antibody: principles and clinical application","volume":"2012","author":"Ahmad","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.omta.2026.201767_bib5","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.3390\/biomedicines11061610","article-title":"Mechanisms of Action and Limitations of Monoclonal Antibodies and Single Chain Fragment Variable (scFv) in the Treatment of Cancer","volume":"11","author":"Rodr\u00edguez-Nava","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.omta.2026.201767_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00018-021-04089-x","article-title":"Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy","volume":"79","author":"Duan","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omta.2026.201767_bib7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.omtm.2018.11.005","article-title":"AAV2\/8 Anti-angiogenic Gene Therapy Using Single-Chain Antibodies Inhibits Murine Choroidal Neovascularization","volume":"13","author":"Hughes","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201767_bib8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ymthe.2022.11.002","article-title":"AAV-mediated neuronal expression of an scFv antibody selective for Abeta oligomers protects synapses and rescues memory in Alzheimer models","volume":"31","author":"Selles","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201767_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101145","article-title":"AAV2-antiVEGFscFv gene therapy for retinal neovascularization","volume":"31","author":"Han","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201767_bib10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.4103\/1673-5374.350192","article-title":"Inflammation and retinal degenerative diseases","volume":"18","author":"Kaur","year":"2023","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.omta.2026.201767_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.preteyeres.2015.06.002","article-title":"Molecular pathogenesis of retinal and choroidal vascular diseases","volume":"49","author":"Campochiaro","year":"2015","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.omta.2026.201767_bib12","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.ophtha.2019.11.026","article-title":"Retinopathy of Prematurity Incidence in Children","volume":"127","author":"Good","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omta.2026.201767_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-Related Macular Degeneration: A Review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.omta.2026.201767_bib14","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(22)02609-5","article-title":"Age-related macular degeneration","volume":"401","author":"Guymer","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.omta.2026.201767_bib15","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41580-023-00631-w","article-title":"Biology and therapeutic targeting of vascular endothelial growth factor A","volume":"24","author":"P\u00e9rez-Guti\u00e9rrez","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omta.2026.201767_bib16","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nature04478","article-title":"Angiogenesis in life, disease and medicine","volume":"438","author":"Carmeliet","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.omta.2026.201767_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","article-title":"Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial","volume":"136","author":"Bressler","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.omta.2026.201767_bib18","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3390\/biom12111629","article-title":"Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration","volume":"12","author":"ElSheikh","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.omta.2026.201767_bib19","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.ophtha.2024.05.025","article-title":"Efficacy of Faricimab versus Aflibercept in Diabetic Macular Edema in the 20\/50 or Worse Vision Subgroup in Phase III YOSEMITE and RHINE Trials","volume":"131","author":"Zarbin","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omta.2026.201767_bib20","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.3390\/ijms25084433","article-title":"Exploring Current Molecular Targets in the Treatment of Neovascular Age-Related Macular Degeneration toward the Perspective of Long-Term Agents","volume":"25","author":"Fragiotta","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omta.2026.201767_bib21","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","article-title":"AAV vectors: The Rubik's cube of human gene therapy","volume":"30","author":"Pupo","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201767_bib22","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omta.2026.201767_bib23","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.omta.2026.201767_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102394","article-title":"Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study","volume":"67","author":"Khanani","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.omta.2026.201767_bib25","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1016\/j.ymthe.2023.09.019","article-title":"Preclinical evaluation of KH631, a novel rAAV8 gene therapy product for neovascular age-related macular degeneration","volume":"31","author":"Ke","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201767_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/pro.5084","article-title":"Thermostability and binding properties of single-chained Fv fragments derived from therapeutic antibodies","volume":"33","author":"Tadokoro","year":"2024","journal-title":"Protein Sci."},{"key":"10.1016\/j.omta.2026.201767_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15010205","article-title":"Ocular Delivery of Therapeutic Proteins: A Review","volume":"15","author":"Shastri","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omta.2026.201767_bib28","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omta.2026.201767_bib29","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(22)00105-2","article-title":"Beyond anti-VEGF: can faricimab reduce treatment burden for retinal disease?","volume":"399","author":"Chia","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.omta.2026.201767_bib30","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1007\/s40265-019-01231-9","article-title":"Brolucizumab: First Approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.omta.2026.201767_bib31","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/IAE.0000000000002566","article-title":"Pharmacokinetic Study of Intravitreal Aflibercept in Humans with Neovascular Age-Related Macular Degeneration","volume":"40","author":"Do","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.omta.2026.201767_bib32","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","article-title":"Intraocular pharmacokinetics of Ranibizumab following a single intravitreal injection in humans","volume":"154","author":"Krohne","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omta.2026.201767_bib33","first-page":"20","article-title":"Addressing the Anti-VEGF Treatment Burden","volume":"25","author":"Hussain","year":"2018","journal-title":"Rev. Ophthalmol."},{"key":"10.1016\/j.omta.2026.201767_bib36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000513048","article-title":"Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration","volume":"244","author":"Tadayoni","year":"2021","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.omta.2026.201767_bib37","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1021\/acs.molpharmaceut.0c01218","article-title":"Ocular Pharmacokinetics of Intravitreally Injected Protein Therapeutics: Comparison among Standard-of-Care Formats","volume":"18","author":"Jakubiak","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.omta.2026.201767_bib38","first-page":"695","article-title":"Ocular Half-Life of Intravitreal Biologics in Humans and Other Species: Meta-Analysis and Model-Based Prediction","volume":"17","author":"Caruso","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.omta.2026.201767_bib39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41434-024-00477-7","article-title":"The AAV2.7m8 capsid packages a higher degree of heterogeneous vector genomes than AAV2","volume":"31","author":"Cui","year":"2024","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201767_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/biot.202300667","article-title":"Enhancing the production of adeno-associated virus (AAV)2 and AAV9 with high full capsid ratio in HEK293 cells through design-of-experiment optimization of triple plasmid ratio","volume":"19","author":"Park","year":"2024","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.omta.2026.201767_bib41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/978-1-61779-095-9_11","article-title":"Vector characterization methods for quality control testing of recombinant adeno-associated viruses","volume":"737","author":"Wright","year":"2011","journal-title":"Methods Mol. Biol."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:12:33Z","timestamp":1789053153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26001023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3117387X26001023"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201767","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of AAV2 anti-VEGF gene therapy using scFv for choroidal neovascularization","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201767","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201767"}}